source
- BeOne Medicines trims five cancer programs and an autoimmune Phase 2 candidateBeOne Medicines has significantly broadened its research portfolio, adding 18 new molecular entities slated for development in 2024 and 2025. Despite the expansion, the company announced it will d…
- STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human diseaseAn international team has found thousands of mini-proteins, including some involved in cell division and DNA repair, as well as several unique to cancer cells.